Estimation of thigh muscle cross-sectional area by dual-energy X-ray absorptiometry in frail elderly patients

Hansen, Ross; Williamson, Dominique A.; Finnegan, Terence P; Lloyd, Brad; Grady, Jodie N.; Diamond, Terrence; Smith, Emma; Stavrinos, Theodora M.; Thompson, Martin W.; Gwinn, Tom; Allen, Barry J.; Smerdely, Peter; Diwan, Ashish D.; Singh, Nalin; Singh, Maria A. Fiatarone

doi:10.1093/ajcn/86.4.952

Cited by 59 publications

(42 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparison of sarcopenia prevalence among studies is rather difficult because of the use of different methodologies: axial CT cross-sectional imaging of SMAs, muscle mass using dual-energy X-ray absorptiometry, or a combination of anthropometric and physical performance measurements [29303132]. Furthermore, even when the same methodology is employed, different cut-offs for sarcopenia are often used (Table 5).…”

Section: Discussionmentioning

confidence: 99%

Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer

et al. 2017

View full text Add to dashboard Cite

PurposeNeoadjuvant chemotherapy has been shown to improve survival in locally advanced gastric cancer, but it is associated with significant toxicity. Sarcopenia and sarcopenic obesity have been studied in several types of cancers and have been reported to be associated with higher chemotherapy toxicity and morbi-mortality. The aim of this study was to assess the prevalence of sarcopenia/sarcopenic obesity in patients with gastric cancer, as well as its association with chemotherapy toxicity and long-term outcomes.Materials and MethodsA retrospective analysis was performed using an academic cancer center patient cohort diagnosed with locally advanced gastric cancer between January 2012 and December 2014 and treated with neoadjuvant chemotherapy. We analyzed body composition (skeletal muscle and visceral fat index) in axial computed tomography images.ResultsA total of 48 patients met the inclusion criteria. The mean age was 68±10 years, and 33 patients (69%) were men. Dose-limiting toxicity was observed in 22 patients (46%), and treatment was terminated early owing to toxicity in 17 patients (35%). Median follow-up was 17 months. Sarcopenia and sarcopenic obesity were found at diagnosis in 23% and 10% of patients, respectively. We observed an association between termination of chemotherapy and both sarcopenia (P=0.069) and sarcopenic obesity (P=0.004). On multivariate analysis, the odds of treatment termination were higher in patients with sarcopenia (odds ratio=4.23; P=0.050). Patients with sarcopenic obesity showed lower overall survival (median survival of 6 months [95% confidence interval {CI}=3.9–8.5] vs. 25 months [95% CI=20.2–38.2]; log-rank test P=0.000).ConclusionsSarcopenia and sarcopenic obesity were associated with early termination of neoadjuvant chemotherapy in patients with gastric cancer; additionally, sarcopenic obesity was associated with poor survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The measure of midarm muscle area by using calipers has been used as a surrogate for total body protein because muscle contains a large percentage of protein (25). Unfortunately, caliper measures of subcutaneous adipose have poor accuracy and poor interobserver agreement (26), muscle area is directly affected by body hydration (27), and the midarm muscle area is poorly correlated to the actual protein status (28).…”

Section: Discussionmentioning

confidence: 99%

Improved 4-compartment body-composition model for a clinically accessible measure of total body protein

Wilson¹,

Strauss²,

Fan³

et al. 2013

The American Journal of Clinical Nutrition

View full text Add to dashboard Cite

show abstract

“…Some non-volitional neurophysiologic and muscle strength assessment tests using electrical and magnetic stimulation techniques of peripheral nerves are available [25]; however, these tests are primarily research tools, and widespread use can be difficult in ICUs, as well as the need for experienced staff and expensive equipment. Muscle mass should also be assessed for diagnosis of sarcopenia; however, as there is no gold standard examination, cross-sectional muscle area and fat-free mass measurements seem to be valid, suitable and commonly used methods [26]. Ultrasonographic measurements of the rectus femoris muscle is sensitive and can demonstrate changes in muscle thickness during ICU stay [27,28].…”

Section: Assessment Methods For Sarcopeniamentioning

confidence: 99%

Sarcopenia in critically ill patients

et al. 2016

View full text Add to dashboard Cite

Sarcopenia occurring as a primary consequence of aging and secondary due to certain medical problems including chronic disease, malnutrition and inactivity is a progressive generalized loss of skeletal muscle mass, strength and function. The prevalence of sarcopenia increases with aging (approximately 5-13 % in the sixth and seventh decades). However, data showing the prevalence and clinical outcomes of sarcopenia in intensive care units (ICUs) are limited. A similar condition to sarcopenia in the ICU, called ICU-acquired weakness (ICU-AW), has been reported more frequently. Here, we aim to examine the importance of sarcopenia, especially ICU-AW, in ICU patients via related articles in Medline.

show abstract

Estimation of thigh muscle cross-sectional area by dual-energy X-ray absorptiometry in frail elderly patients

Cited by 59 publications

References 26 publications

Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer

Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer

Improved 4-compartment body-composition model for a clinically accessible measure of total body protein

Sarcopenia in critically ill patients

Contact Info

Product

Resources

About